Gather-ed - Improving the Care of Patients with Advanced Renal Cell Carcinoma

Target Professions:	DO, MD, Nurse Practitioner, Physician Assistant, Nurse
Target Specialties:	Family Medicine, Hematology, Hematology/Oncology, Internal Medicine, Oncology, Urology, Women's Health
Credits Available:	3.75 AMA PRA Category 1 Credit™

Renal cell carcinoma (RCC) remains the most common variety of renal cancer, representing 90% of the diagnoses. Within the United States (US), it is a relatively common malignant caner, ranking as sixth and tenth most common for men and women respectively. Yet, the incidence has been slowly but steadily rising over the past thirty years. While localized RCC has a high survival rate, metastatic RCC only has a 5-20% 5-year survival rate. Previous forms of therapy at this stage had variable efficacy and poor tolerability in these advanced stages. The development of several agents has improved RCC outcomes and have improved tolerability: vascular endothelial growth factor inhibitors (VEGFi), mammalian target of rapamycin inhibitors, and immunotherapies. Of note, two main combinations of are approved in patients with RCC: (1) tyrosine kinase inhibitors (TKIs) with immuno-oncology (I-O) therapies and (2) two I-O agents. Educational programs that focus on this new and emerging approach are needed to aid clinicians in understanding the proper and safe use of I-O combinations. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with renal cell carcinoma.

CME/CE Accreditation Information

Self Study

Improving the Care of Patients with Advanced Renal Cell Carcinoma - Baseline Assessment

The following questions are designed to assess your knowledge and practice of patients with renal cell carcinoma.
Self Study Module 1: RCC Treatment: IO/IO and IO/TKI

This module will cover treatment options in renal cell carcinoma.
Self Study Module 2: Managing RCC Immune-Related Adverse Events (irAEs)

This module will cover the management of immune-related adverse events in renal cell carcinoma.
Self Study Module 3: RCC Cancer-Related Distress

This module will cover cancer-related distress in renal cell carcinoma.
Improving the Care of Patients with Advanced Renal Cell Carcinoma - Final Assessment

The following questions are designed to assess your knowledge and practice of patients with renal cell carcinoma.

Live Group Discussions

Meet and Greet

Please join me for a brief kick off where you'll have a chance to greet other group members and discuss our collective goals and priorities for the next few weeks. I’m really looking forward to seeing you.
Live Group Discussion #1: Key Insights on Renal Cell Carcinoma

This virtual live discussion provides an opportunity for the group to convene with their group leader to discuss aspects of the self-study learning modules.
Live Group Discussion #2: Renal Cell Carcinoma Take-Home Messages: Putting the Evidence to Practice

This virtual live discussion provides an opportunity for the group to convene with their group leader to discuss aspects of the case study responses and action plans.

Group Case Study

Renal Cell Carcinoma: Jacob's Case

This group task activity has been designed for the learner to explore a patient case study and to apply the knowledge they have learned throughout the activity to determine the most appropriate way to treat the patient.

My Action Plan

Create an Action Plan

In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with RCC.

Curriculum is Currently Closed

Thank you for your interest. Currently, the curriculum is closed for enrollment but we encourage you to keep an eye out for future opportunities or alternative programs that might align with your educational goals.

View Other Offerings